subject: Aarkstore Enterprise---immucor, Inc. (blud) - Financial And Strategic Analysis Review [print this page] Immucor, IncImmucor, Inc. (Immucor) is a global in-vitro diagnostics company engaged in the development, production and sale of a full line of reagents and automated systems. The company develops products that are used in performing the tests to detect and identify certain properties of the cell and serum components of human blood before the process of blood transfusion. Its key customers include hospitals, clinical laboratories and blood banks. Immucor also provides fully automated instruments for daily function of blood banks, transfusion laboratories and small- and medium-sized hospitals. Its operations are concentrated in the US, Canada, Europe and Japan.
Immucor, Inc. Key Recent Developments
Jul 26, 2010 Immucor Appoints Mason Morfit To Board
Jul 22, 2010 Immucor Reports Net Income Of $21.5 Million For Q4 Fiscal 2010
Jul 22, 2010 Immucor Reports Net Sales Of $329.07 Million In Fiscal 2010
Jun 02, 2010 Immucor Provides Fiscal 2011 Guidance
Mar 31, 2010 Immucor Reports Net Income Of $20 Million In Q3 Fiscal 2010
This comprehensive SWOT profile of Immucor, Inc. provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including,
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company